XML 50 R39.htm IDEA: XBRL DOCUMENT v3.25.3
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 24 Months Ended
Sep. 28, 2025
Sep. 29, 2024
Sep. 28, 2025
Sep. 29, 2024
Sep. 28, 2025
Restructuring charges/(credits):          
Employee terminations $ 124 $ 25 $ 360 $ 1,009  
Asset impairments 111 111 328 177  
Exit costs 2 82 96 145  
Restructuring charges/(credits) [1] 237 217 784 1,331  
Transaction costs [2] 0 0 0 5  
Integration costs and other [3] 49 96 162 333  
Restructuring charges and certain acquisition-related costs 286 313 945 1,669  
Inventory write-offs––recorded in Cost of sales 33 0 33 0  
Additional depreciation––asset restructuring [4] 4 8 11 16  
Implementation costs [5] 105 75 234 238  
Total costs associated with acquisitions and cost-reduction/productivity initiatives 423 398 1,150 1,930  
Biopharma [Member]          
Restructuring charges/(credits):          
Restructuring charges/(credits) 240 141 451 1,200  
Biopharma [Member] | Manufacturing Optimization Program [Member]          
Restructuring charges/(credits):          
Restructuring charges/(credits) 117   (295) 1,300  
Biopharma [Member] | Realigning Our Cost Base Program [Member]          
Restructuring charges/(credits):          
Restructuring charges/(credits) 107   669 (69) $ 2,600
Other (income)/deductions––net [Member]          
Restructuring charges/(credits):          
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net (6) 2 (74) 7  
Cost of sales [Member]          
Restructuring charges/(credits):          
Additional depreciation––asset restructuring [4] 3 6 10 11  
Implementation costs [5] 26 30 72 95  
Selling, informational and administrative expenses [Member]          
Restructuring charges/(credits):          
Additional depreciation––asset restructuring [4] 0 2 0 5  
Implementation costs [5] 26 13 46 77  
Research and development expenses [Member]          
Restructuring charges/(credits):          
Additional depreciation––asset restructuring [4] 1 0 1 0  
Implementation costs [5] $ 53 $ 33 $ 116 $ 66  
[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $240 million for the three months ended September 28, 2025 (including charges of $117 million for our Manufacturing Optimization Program and charges of $107 million for our Realigning our Cost Base Program), (ii) charges of $451 million for the nine months ended September 28, 2025 (including charges of $669 million for our Realigning our Cost Base Program and credits of $295 million for our Manufacturing Optimization Program), (iii) charges of $141 million for the three months ended September 29, 2024 (primarily including charges for our Realigning our Cost Base Program) and (iv) charges of $1.2 billion for the nine months ended September 29, 2024 (including charges of $1.3 billion for our Manufacturing Optimization Program and credits of $69 million for our Realigning our Cost
Base Program). For the nine months ended September 28, 2025 and September 29, 2024, Employee terminations include revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.
[2] Represents external costs for banking, legal, accounting and other similar services.
[3] Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.
[4] Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[5] Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.